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 ABSTRACT 
Androgens are involved in the development of prostate cancer. Both UGT2B17 and 
CYP7B1 are involved in the metabolism of androgens and are highly abundant in the 
prostate. 
Deletion of the UGT2B17 gene is associated with low or undetectable urinary 
testosterone levels. The phenotypic outcome of the deletion was studied by quantifying 
the UGT2B17 mRNA expression in normal prostate tissues in individuals with 
different genotypes. Additionally a case–control study of prostate cancer was 
performed, including 176 cases diagnosed with prostate cancer and 161 healthy 
controls. Individuals homozygous for the insertion allele expressed 30 times higher 
levels of UGT2B17 mRNA in prostate tissue compared to heterozygous carriers, who 
had a significantly increased risk of prostate cancer (OR 2.15, CI 1.29–3.58).  
We screened the human CYP7B1 gene for possible polymorphisms. Only one single 
polymorphism was detected, a C–G change in the promoter. Expression studies with 
reporter constructs showed significantly higher transcriptional activity of the G variant 
in Hek293 cells (2.7-fold ) The allele frequency was 4.04% in Swedes and 0.33% 
among Koreans. No association to prostate cancer could be found when tested in the 
previously described case–control study. 
In a population-based case-control study including 507 women with miscarriage in the 
first trimester of  pregnancy and 908 controls with a normal first-trimester pregnancy, it 
was determined whether the cytochrome P450 1B1 (CYP1B1) Val432Leu 
polymorphism is associated with risk of miscarriage. Carriers of the Val/Val genotype 
were at higher risk of miscarriage in the first trimester of pregnancy compared to 
Leu/Leu carriers (OR 1.46; 95% CI 1.02–2.08). 
When the same single nucleotide polymorphism (SNP) was investigated in a case–
control study of recurrent miscarriages, 206 women who had had three or more 
miscarriages were compared to 618 controls who had at least one pregnancy and who 
never miscarried. The OR for Val/Val genotype carriers was 1.00 (95 % CI 0.64–1.56), 
giving no association with repeated miscarriage. Thyroid disease and smoking was 
significantly associated with recurrent miscarriages. 
The association between abnormal progression of the first stage of labour and 
expression of enzymes involved in the androgen metabolism as well as estrogen 
receptors alpha and beta in human myometrium was investigated. Twenty women with 
an abnormal cervical ripening were compared to 12 women with a normal progression 
of cervical dilatation and 15 women that had not been in labour. Estrogen receptor 
alpha had a significant role in the progression of human labour. Estrogen receptor beta, 
AKR 1C1-4, CYP 19A1, CYP7B1 and 5alpha reductase type 1 expression in the 
myometrium are independent of the progression in the first stage of labour. 
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1 INTRODUCTION  
1.1 GENERAL INTRODUCTION 
 
Reproductive steroid hormones are divided into three major groups; estrogens, 
progestins and androgens. These are of great importance in the sexual development and 
health of men and women, and are interact with all organs in the body including the 
brain. 
Androgen is a Greek word derived from ανδρας (man) and γεννω (giving birth). 
Androgens are steroids mainly metabolised by the testicles, which are necessary for the 
development of gender and primary and secondary sex characteristics of the male 1. 
Androgens have been in focus for years as hormones that can influence the 
development and progression of prostate cancer, the most common form of cancer in 
men (34.1 % of all male cancers in Sweden 2007 ref SOS Cancer i siffror 2009 ).  
Androgens (e.g. testosterone and dihydrotestosterone) are also formed in 
the ovaries. However, the mean total levels of testosterone in women are only 1/10 of 
those in men 2. The function and effects of these hormones, nevertheless, also are of 
importance in women, an example is the androgenic contribution to PCO (polycystic 
ovary syndrome). For both men and women, lower than normal levels of circulating 
androgens, have been associated with sexual dysfunction although the exact 
mechanisms have not been established 3, 4.  
Estrogens (e.g. estrone, estrone sulphate, estradiol, estriol) are mostly 
associated with sexual development of the female since they are required for the normal 
maturation of female primary and secondary sex characteristics during adolescence and 
for the onset of fertility in women. During fertile life, estrogens are mostly produced by 
the growing follicle, in the ovary. In pregnancy, the placenta is the main steroid 
producing organ, introducing very large amounts of circulating estriol and progesterone 
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5. Later in life estrogen levels will naturally decline, with post-menopausal values 
falling below those measured in the male (figure 1). 
Target organs for estrogens are mainly the uterus and the breast and for 
testosterones the prostate and hair follicles. 
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1.2 SEX DIFFERENTIATION 
The mammalian embryo is initially formed by precursor tissues that are the same 
irrespective of chromosomal sex. The precursor tissue is the indifferent gonad, which 
will be differentiated to testis or ovary depending on the existence of a Y chromosome. 
The Müllerian and Wolffian duct systems are the respective precursor tissue for the 
female and male internal genitalia, and the urogenital sinus which gives rise to external 
genitalia 6. 
 
Sexual development in the mammalian embryo depends on three sequential 
processes. The first step, which occurs at fertilisation, is to establish the genetic sex by 
the content of the sex chromosomes. Gender is determined by the presence or absence 
of a Y chromosome. When present, the Y chromosome dominates over the X 
chromosome (even if multiple), leading to male sex differentiation 7. 
The Y chromosome will be the factor that leads to the second step of 
development of the male, the differentiation of the indifferent gonad to testis. 
Experimental studies have shown that ovarian differentiation is the “default pathway” 
in mammals 6. In males, this pathway is “overridden” by the testis determining gene 
which is located on the Y chromosome (SRY) 8. It seems that SRY acts on a single 
gene SOX9, which then drives the Sertoli cell formation giving rise finally to the testis. 
In the female SOX 9 is down-regulated. It has been thought that this down-regulation is 
passive, however a hypothesis that has been questioned. 
In the third step, the final gonadal phenotype arises depending on the presence 
(male) or absence (female) of three hormones, the anti Müllerian hormone (AMH), 
testosterone (T) and dihydrotestosterone (DHT). In the male, the foetal testis secretes 
AMH that affects the Müllerian ducts, which otherwise (in the female) are precursors of 
the fallopian tube, uterus and the upper part of vagina 9. Separately, testosterone 
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secretion from the testis drives growth and differentiation of the Wolffian duct system, 
giving rise to male internal genitalia, epidydimis, vas deferens and seminal vesicles 10. 
The external male genitalia (prostate, scrotum, penis and male urethra) will develop 
when the urogenital sinus is affected by DHT, the 5-alpha reduced metabolite of 
testosterone 11. As noted, female development ensues in the absence of these 
androgenic steroids, otherwise derived from the foetal testis. The preeminent role of 
these hormones in male development has been proved by experimental studies showing 
that the female foetus can be masculinised if androgens are provided even if testis are 
missing, as in the androgenital syndrome5, 12. 
Although the expression of androgens in the embryonic stage, are closely related 
to normal male development, androgens have been found in females throughout life. 
(fig 1)  
Figure 1 
 
Approximate mean sex steroid levels in plasma in males and females 
Variation in steroid levels is shown as percent of the maximum mean testosterone (T) 
in males and the maximum mean estradiol (E) in females across the life stages.  
Published in final edited form as: 
Nat Rev Genet. 2008 December; 9(12): 911–922. 13 
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1.3 STEROID METABOLISING ENZYMES 
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1.4  PROSTATE CANCER  
 
Prostate cancer is the most common cancer form in man (comprising34.1% of all 
male cancers in Sweden 2007 ref SOS Cancer i siffror 2009). The clinical focus in 
recent years has been on early diagnosis of prostate cancer, with emphasis on general 
screening with PSA (prostate specific antigen). Several studies would appear to support 
the utility of the PSA screening. For example, a large European study on PSA testing 
found a 20% decline in prostate cancer related mortality among those men that were 
screened with PSA 14. Further evidence was provided in a recent Swedish publication 
on PSA screening showing as much as a 50 % decrease in prostate cancer related 
mortality with PSA screening15.  
Enthusiasm for PSA screening programs, however, has been tempered by one 
major drawback, of PSA screening programs - the high percentage of overtreatment 
that is required to achieve the benefits of reduced mortality. Thus, it was estimated that 
to prevent one prostate cancer related death, 48 men had to be treated 14. Since the 
treatment for localised cancer is prostatectomy or brachytherapy, adverse effects of 
impotence and incontinence have to be considered 16, 17.   
The incidence and the relative 10 year survival rates in prostate cancer in the 
Nordic countries have been increasing substantially since 1964, probably an effect of 
the introduction of PSA testing 18 . However, the corresponding mortality in prostate 
cancer has been stable. 
It is not surprising, then, that treatment of localised prostate cancer has been a 
matter of intense discussion and debate, which is further energized by the fact that the 
risk of dying due to localised prostate cancer is rather low (3.6 % 10-year mortality 
without treatment) 19. When treatment is given to all prostate cancer patients, the 
mortality rate due to the disease is lowered by 34 % but not the overall mortality when 
compared to “watchful waiting” 20. 
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The importance of androgens in the development and progression of prostate 
cancer is widely known. It had been observed, for example, that eunuchs do not 
develop prostate cancer. In 1941, Huggins 21 reported that orchidectomy is an effective 
way to ameliorate the disease symptoms and to delay progression of advanced prostate 
cancer. The mechanisms underlying the androgenic influences on the etiology of 
prostate cancer are not well-understood. This is illustrated by a study in which men 
were given finasteride, a drug that is inhibiting the biotransformation of testosterone to 
the more potent metabolite dihydrotestosterone (DHT). This treatment reduced the 
incidence of prostate cancer overall, but was also found to accelerate the progression of 
more aggressive forms of prostate cancer. 22 
In order to improve the prognosis, without overtreatment, new diagnostic 
indicators are searched for such as gene polymorphisms affecting the metabolism of 
androgens. 
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1.5 PREGNANCY 
 
In pregnancy, the foetus and mother are interrelated by signalling mostly through 
the hormonal environment. The growing foetus can influence or control its own growth 
by signalling to the mother. It has proven useful to consider the sex steroid metabolism 
in the foetus, mother and placenta as a unit, where each component is seen as 
contributing to the metabolism of the others. This concept of the “fetoplacental unit” 
was introduced by Egon Diczfalusy in 196423. 
Progesterone, produced by the corpus luteum until the 10th week of gestation, is 
believed to be important for the maintenance of human pregnancy. Thereafter, the 
placenta becomes the predominant source for the production of large amounts of 
hormones (including progesterone and estrogens). The steroid-hormone precursor 
cholesterol must be provided by the maternal circulation, given that no cholesterol is 
produced within the placenta itself.  
The uptake of cholesterol in the placenta is regulated by estradiol, which is found 
to increase the LDL-receptor gene transcription in baboons 24. Estradiol is also 
enhancing the effect of P450scc (encoded by the CYP11A1 gene) that is the enzyme 
metabolising cholesterol to pregnenolone, the substrate from which progesterone is 
produced 25. 
The androgens are the basic precursors of estradiol. In early pregnancy, they are 
provided from the maternal circulation. Later in pregnancy, the estrogen production is 
under control of the foetus, thus dehydroepiandrosterone sulphate (DHAS) is mostly 
produced in the foetus, before being converted in the placenta to testosterone, which 
then is aromatised to estradiol. Finally, estradiol will be secreted into the maternal 
circulation. 
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1.5.1 Miscarriage AND Repeated miscarriage 
 
Ten to twenty percent of all clinically recognized pregnancies end in miscarriage 
26 27. “Recurrent miscarriage,” codified as 3 or more consecutive miscarriages, is 
experienced by 1-2 % of couples. 28. 
The prevalence of recurrent miscarriage is higher than expected 28, suggesting 
common explanatory factors for the miscarriages. 
It has been estimated that in over half of miscarriages, a chromosomal 
abnormality is present in the foetus 29 30, 31. Major parental chromosomal disorders such 
as balanced translocations explain 3-6% of miscarriages 32, 33. 
Maternal age > 35 years is a major factor for miscarriage, largely through the 
clear association between maternal age and risk of chromosomal abnormality in the 
foetus 31, 34, 35. 
Autoimmune factors (such as lupus anticoagulant and cardiolipin antibodies) also 
are well known to increase the risk of miscarriage 36. The well-established treatment of 
women with known antiphospholipid syndrome and recurrent miscarriage with aspirin 
and fractionate heparin appears to lower miscarriage rates at least in early pregnancy37, 
38. 
Thrombophilia is a diverse group of coagulation disorders associated with a 
predisposition to thrombosis. Except for antiphospholipid syndrome other conditions 
included are activated protein C (APC) resistance inherited through a mutation in factor 
V Leiden, deficiency of protein C and S, mutation in the prothrombin gene and 
antithrombin deficieny 39. Although these conditions give an increased risk for 
thrombosis, there was no decreased risk found for miscarriage when aspirin and 
fractionate heparin was given to these women 40.  
 In a Cochrane metaanalysis in 2009 studying low dose aspirin treatment 
in women with repeated miscarriage but no trombophilia, showed no benefit of 
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anticoagulant treatment either. 41. In conclusion, only women with known 
antiphospholipid syndrome will benefit from anticoagulant treatment. 
 
Maternal exposure to antidepressants is another variable that has been linked to 
elevated risk for miscarriage 42. It is not known, however, whether the association is 
better explained by the drug treatment or by factors related to the underlying disease. 
The mood of the pregnant women, more generally, is taken to be of relevance to 
pregnancy outcomes. For example, the practice of “love and tender care” has been 
shown to reduce the recurrence of miscarriages 43. 
The importance of progesterone produced in the ovary during early pregnancy 
has lead to trials with corpus luteum-enhancing treatments, where HCG (human 
chorionic gonadotropin) injections or progestines are given, for prevention of 
miscarriage. Cochran meta analysis of these treatments studies, however, do not affirm 
consistent or reliable effects on pregnancy outcomes. Thus, neither progestagens nor 
HCG is recommended for the treatment of repeated miscarriages 44, 45. 
It has been postulated that immunologic aberrations may be responsible for 
recurrent miscarriage. The physiological mechanisms that allow a mother to tolerate her 
semi-allergenic baby are unclear. Defects in molecular immunosuppressive factors at 
the local decidual/trophoblast level have been implicated 46. Therefore, there have been 
several attempts to modulate the immunological response in the mother. These 
treatments were evaluated in a Cochrane review, but no effect on risk of miscarriage 
was found 47. 
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1.5.2 Dysfunctional labour  
 
The mechanism of initiation and progression of labour are still not known. The 
steroidal hormones, progesterones and estrogens are increasing during pregnancy. A 
rise in estradiol and decrease of progesterone are known to initiate labour in other 
species than humans 48. However in studies measuring hormonal levels in women prior 
to the onset of labour, a similar alteration in steroidal levels in peripheral blood, could 
not be shown 49. 
 
Figure 3 
A model of induction of labour in sheep showing the interaction in 
the fetoplacental unit that leads to labour. (Speroff 2005) 
 
Adrenal Gap junctions 
Contractions Prostaglandin
Estradiol
DHA 
3β-OH dehydrogenase
DHA-sulfate
Fetus
Placenta
Uterus 
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Estrogens are important for human labour since in pregnancies with low estrogen 
levels, as in anencephalia of the foetus, labour will not start in time. Progesterone 
administration on the other hand might prevent preterm delivery in high-risk singleton 
pregnancies 50. This effect does not seem to be related to initial progesterone levels. 
The increase of salivary estriol and the estriol/progesterone ratio throughout 
gestation seem to be of importance. The estriol/progesterone ratio rises even more 
dramatically immediately before term as well as in preterm labour 51. In addition, two 
consecutively elevated salivary estriol measurements have been strongly associated 
with impending preterm delivery 52. 
It has also been shown that the onset of labour in humans is related to relative 
progesterone withdrawal due to an increase in progesterone receptors in the 
myometrium 53 with a corresponding up-regulation of the estrogen receptor alpha 
leading to a higher responsiveness of the myometrium to estrogen prior to labour. 54 
Estradiol has also been shown to successfully induce labour, an effect 
comparable to that shown for prostaglandins that are dominating clinical practice today 
55 56 57 58. High estradiol levels, in the myometrium, are believed to increase the local 
production of prostaglandins. 
The most common indication for caesarean section among nulliparous women is 
dystocia or abnormal labour. Dystocia is characterised by absence of a successful 
progression of labour that can be due to; fetomaternal disproportion, unfavourable 
presentation of the foetus during birth and arrest in the progression of labour related to 
the dysfunction of the uterus and cervical ripening 59. 
The standard treatment for dystocia when a lack of effective contractions of the 
uterus is suspected is the usage of intravenous oxytocin. Although oxytocin is widely 
used, the number of women undergoing caesarean section is steadily increasing in the 
western world. At the same time the adverse effects of oxytocin has been in focus for 
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research and active management of labour that includes an early usage of oxytocin has 
been questioned60. A more recent meta-analysis has shown only a modest effect, if any 
at all, of the usage of early oxytocin treatment (along with early amniotomy) on the 
caesarean section rate 61. Therefore, more knowledge about the mechanisms of labour is 
needed. 
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2 THE PRESENT STUDY 
2.1 AIMS 
The aim of this thesis was to investigate possible effects of genetic variation of 
androgen and estrogen metabolism on human reproduction and reproductive organs. 
 
The specific aims for each study were as follows: 
 
Paper 1: To investigate the impact of the UGT2B17 deletion polymorphism on prostate 
cancer risk and further to investigate the effect of the deletion on the expression of 
UGT2B17 in the prostate. 
 
Paper 2: To investigate the occurrence of single nucleotide polymorphisms in the 
CYP7B1 gene and to analyse possible effects of a novel polymorphism identified in the 
CYP7B1 gene on the risk of prostate cancer. 
 
Paper 3: To investigate the effect of the CYP1B1 Val432Leu single nucleotide 
polymorphism (SNP) on the risk of miscarriage in the first trimester. 
 
Paper 4: To determine whether the risk allele found in study 3 also is a risk factor for 
repeated miscarriage and, further, to describe the clinical characteristics of a population 
of women with repeated miscarriages. 
 
Paper 5: To determine whether expression of different androgen metabolising enzymes 
and estrogen receptors is affected in the myometrium of women who have had a 
dysfunctional labour. 
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2.2 METHODS 
 
2.2.1 Subjects  
 
2.2.1.1 Papers 1-2 
 
One hundred seventy six men, age 51–79 years, with known prostate cancer, 
were recruited consecutively in Örebro County Sweden. One hundred sixty one men 
were randomly selected from the county population register and matched for age (50–
59, 60–69 and 70–79 years) served as control group.  
In paper 1, a Korean population of 156 healthy men and women were used for 
comparison with the Swedish controls.  
 
2.2.1.2 Paper 3  
 
Four hundred ninety-eight women were recruited when diagnosed with 
miscarriage in the first trimester of pregnancy (6–12 completed weeks of gestation) 
from Akademiska University hospital. Nine hundred twenty-nine control subjects were 
recruited from the maternal care centers in the same catchment area.  
 
2.2.1.3 Paper 4 
 
Two hundred twelve women with three or more verified consecutive miscarriages 
in the first or second trimester of pregnancy (5-21 completed weeks of gestation) were 
recruited as cases. Six hundred thirty-six control subjects were randomly chosen from 
the Uppsala University biobank of pregnant women. Controls had at least one full term 
pregnancy and no history of miscarriage.  
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2.2.1.4 Paper 5  
 
Three groups of women were included in the study: 1) 15 women planned for 
caesarean section before start of labour 2) 12 women with a normal progression of 
cervical dilatation until the labour ended in an emergency caesarean section and 3) 20 
women with an abnormal progression of cervical dilatation that ended with an 
emergency cesarean section.  
 
2.2.2 Laboratory methods 
 
2.2.2.1 Genotyping 
  
DNA was extracted from blood or buffy coat using a commercial kit and stored at 
–20 until analyzed.  
A fluorogenic 5' nuclease polymerase chain reaction (PCR) was performed 
according to the principle reviewed by Livak62, with a primer pair and two different 
probes identifying the two alleles. (Papers 1,3 and 4) 
In paper 2, two primer pairs corresponding to the gene (ins) or to the area were 
the deletion is included (del) were used for the PCR. The products were identified 
either on a gel or by real time PCR (Taqman). 
  
2.2.2.2 Single Nuclotide Polymorphism Detection 
 
2.2.2.2.1 In silico analysis 
Potential polymorphisms in the CYP7B1 gene were identified using the EST 
database and a BLAST alignment tool. When the indicated mutations gave rise to a 
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nonconservative amino-acid change, we performed a PCR-direct sequence analysis to 
verify these potential polymorphisms. (Paper 2) 
 
2.2.2.2.2 Single-stranded Conformation Polymorphism Analysis 
 
Single stranded PCR products of the gene were separated on polyacrylamide gels. 
The DNA fragments were visualized by silver staining. DNA fragments that have 
sequence differences will be separated on the gel. These fragments are then purified 
using PCR purification kit and sequenced. (Paper 2) 
 
2.2.2.3 Reporter Gene assay  
 
Plasmids were constructed by PCR amplification using human genomic DNA as 
template with the forward and reverse primers including the part of DNA of interest. 
The amplification products were subcloned into a pCR2.1 vector, and then subcloned 
into a luciferase vector. HepG2 (liver) and Hek293 (kidney) cells were transfected with 
the luciferase vector containing the DNA sequence of interest. The cells were incubated 
and luciferase activity was determined using a luminometer. (Paper 2) 
 
2.2.2.4 Gene expression 
 
Total RNA was extracted from the myometrial and prostate samples. The purity 
and quality of myometrial RNA was evaluated in an Agilent analyser. Synthesis of 
complementary DNA (cDNA) from RNA samples was performed using a commercial 
kit. 
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Relative quantification of cDNA was done using real time PCR (Taqman). The 
gene expression was normalized against an endogenous housekeeping gene. (Papers 1 
and 5) 
 
. 
2.2.3 Statistical methods 
 
Genotype and allele associations were assessed with χ2-test, binary and nominally 
logistic regression. ORs were used as an approximation of relative risks, using 95% 
confidence intervals (Papers 1-4). 
 
The statistical analysis for expression mRNA was performed using t-test for 
independent samples (paper 5) and the non parametric Mann-Whitney U-test (Papers 1 
and 5). A p-level of 0.05 was considered as significant. 
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2.3 RESULTS  
 
2.3.1 Papers 1 and 2 
 
Individuals lacking one or two copies of the insertion (ins) (del/del or del/ins) of 
the UGT2B17 gene were at significantly increased risk of prostate cancer (OR 2.05) 
(table 1). The expression of UGT2B17 was found to be significantly lower in prostate 
tissues derived from individuals with deletion of one of the alleles as compared to that 
of ins/ins individuals (P <0.02, Mann–Whitney U-test). The ins/ins individuals 
exhibited approximately 30 times more UGT2B17 mRNA in the prostate tissues than 
individuals with only one ins allele (ins/del). 
 
A functional SNP in the promoter region of the CYP7B1 gene was reported, 
otherwise the gene was highly conserved. The SNP was more frequent among Koreans 
than Swedes (p = 0.002). No association with prostate cancer risk could be 
demonstrated. 
 
2.3.1.1 Table 1 
 
Odds ratios for having prostate cancer for UGT2B17 del/ins and del/del variants 
compared with ins/ins carriers 
  OR (adjusted) CI 
UGT2B17 ins/ ins  1 Reference 
 ins/del 2.15  1.29–3.58 
 
 
2.3.2 Papers 3 and 4 
 
Relative to carriers of the Leu/Leu genotype, we found that carriers of the 
Val/Val genotype were at increased risk of first trimester miscarriage (OR 1.46). 
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Adjustments for covariates (maternal age, daily smoking, caffeine intake, earlier 
miscarriage, alcohol intake and pregnancy symptoms) did not essentially change this 
association (table 2).  
The unadjusted odds ratio for recurrent miscarriages among Val/Val genotype 
carriers relative to carriers of the Leu/Leu genotype was 1.00 (table 2).  
Independent explanatory factors for recurrent miscarriage in this population were 
thyroid disorders, other disorder with known association with recurrent miscarriage and 
smoking (Paper 4). 
 
2.3.2.1 Table 2 
 
Odds ratios for miscarriage and repeated miscarriage for carriers of the CYP1B1 
Val/Val and Val/Leu variants compared with Leu/Leu carriers. 
 
  OR (adjusted) CI 
Miscarriage  Leu/Leu 1 Reference 
(Paper 3) Val/Val 1.46 1.02–2.08 
    
Repeated miscarriage  Leu/Leu 1  
(Paper 4) Val/Val 1 0.64 – 1.56 
    
 
 
2.3.3 Paper 5 
 
Uterine estrogen receptor alpha (ERα) was up-regulated in the women with 
normal progression of labour compared to those with abnormal progression (p = 0.008) 
and to those not in labour (p = 0.003). The expression of ERβ, 5AR1, AKR1C1 and 3, 
CYP19A1 and CYP7B1 did not differ in the group of women with abnormal labour 
compared to the two control groups of women.  
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3 GENERAL DISCUSSION  
 
The aim of this thesis was to investigate possible effects of genetic variation of 
androgen and estrogen metabolism on human reproduction and reproductive organs. 
 
CYP7B1, together with 3a-HSD, 3b-HSD, 5 alpha-reductase as well as 
UGT2B17 gene are enzymes known to determine the levels of androgens and their 
metabolites. Genetic variations in these genes are important to study, in order to 
understand the mechanisms that promote the development and growth of prostate 
cancer. Identifying risk genotypes may also be important for physicians, when choosing 
therapy in order to offer the treatment with the best prognosis in combination with the 
lowest possible side effects. 
This study has shown that individuals with two copies of UGT2B17 gene have 
significantly lower risk of developing prostate cancer compared to carriers of only one 
copy. (Paper 1) Additionally, it was found that the deletion of one allele is associated 
with significantly lower mRNA levels in the prostate, further supporting the 
epidemiological results that individuals exhibiting two gene copies of UGT2B17 are 
protected from androgen exposure in the prostate and thus have a decreased risk of 
developing prostate cancer. Our results are consistent with a previous report, which 
showed that Caucasian individuals, homozygous for the deletion allele exhibit a 
significantly increased risk for prostate cancer compared with insertion carriers (ins/ins 
and ins/del)63. The genotyping method used in that study did not distinguish between 
heterozygous (ins/del) and homozygous (ins/ins) genotypes, thus they were not able to 
compare the del carriers with individuals homozygous for the ins allele, as in this 
report. A later study, that also used a genotyping method that did not distinguish ins 
homozygous carriers from heterozygous carriers, concluded that no difference in risk 
exists to del/del carriers 64. They used however, a reference group that included high 
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risk (ins/del) mixed with low risk individuals (ins/ins), thus no difference was found. In 
a study by Gallagher 65 no difference was observed, however they have been criticized 
for including individuals with deviating PSA levels in the control group. The risk of 
including individuals with prostate cancer in the control group is bias versus null 66. 
A novel functional SNP in the CYP7B1 was identified (Paper 2). We observed 
differences between the mutant variants in promoter activity in Hek293 cells, whereas 
no enhancement of activity was observed with HepG2 cells. The difference could be 
explained by variation in the abundance of C/EBPb and/ or other proteins in the HepG2 
and Hek293 cells. When the allele frequency of this SNP was analysed a difference was 
seen between Swedes and Koreans, which did not have an effect on prostate cancer risk 
in the Swedish population. This may be explained by lack of power, on the other hand 
the mutant allele was not common in the Swedish population giving a low impact in 
this population. 
One limitation of these studies is small sample size, which could explain why we 
could not find any association with tumour stage or differentiation grade for the 
UGT2B17 deletion. However, the strengths of the study are that the healthy controls 
were age matched and recruited from the same community as the cases.  
The CYP1B1 polymorphism was studied in papers 3 and 4. A common 
polymorphism that was earlier found to affect steroid metabolism was associated with 
first trimester miscarriage and was modifying the effect of coffee drinking. This result 
was however not confirmed in a case-control study on repeated miscarriages (Paper 4). 
The results are in line with Saijo and colleagues who did not find any association 
between this polymorphism and risk of two or more miscarriages in Japanese women 
67. In conclusion, the “risk polymorphism” might be associated with miscarriage; 
however, it is not an absolute obstacle for maintenance of a pregnancy. 
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As physicians, finding a simple explanation, for the diseases that strikes our 
patients would be fantastic! Miscarriage is a condition that has a multifactorial cause. 
The purpose of research concerning miscarriages is not to prevent every miscarriage 
but to increase the knowledge of how human pregnancy is thriving and which factors 
may affect a normal progression of pregnancy. Miscarriage is Natures way of selecting 
healthy pregnancies. Women that have had repeated miscarriages are at higher risk for 
complicated pregnancies 68 69 and, as shown in this study, may also develop thyroid 
disease later in life. 
 As the study subjects in paper 4 had their miscarriages up to eighteen years 
earlier, we were also able to confirm their current health status as well as changes in 
health status across time. Women with thyroid disease at the time of the miscarriage, or 
even more evident, with current thyroid disease were clearly overrepresented among 
subjects with recurrent miscarriage in comparison with women who never miscarried. 
Although our controls may be younger when studied, giving a misleadingly low disease 
frequency in comparison with our cases, the prevalence of thyroid disorders in the 
general population is reported substantially lower (9 %) than found among our cases 
with recurrent miscarriages 70. Our findings support the notion that repeated 
miscarriages may indicate subclinical thyroid disease, which ultimately may be 
diagnosed years after the miscarriages.  
We have also, with relative certainty, confirmed that smokers have higher risk of 
repeated miscarriage 69. However, it must be emphasized that the odds ratio for 
smoking may be overestimated as smoking gradually over the years has become more 
infrequent among Swedish women, resulting in lower smoking frequency in our 
controls. Whether smoking is a risk factor for spontaneous miscarriage is still a 
controversy 34, 71, 72 as self-reported data of a risk factor that is known to be harmful 
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during pregnancy may lead to reporting and recollection bias in either way, a factor that 
our data also may suffer from.  
The small sample size of this study may be a limitation. On the other hand, to our 
knowledge, earlier studies have involved smaller number of cases, which makes our 
study unique. This investigation is furthermore strengthened by the large number of 
population based controls, residing in the same area as the cases. We were also able to 
match for age, an otherwise disturbing confounder.  
The degree of progression of cervical dilatation during labour is the main 
indication of normal progression of labour. We have shown that when the cervical 
dilatation is normal, ERα mRNA expression in the lower uterine segment is 
significantly up-regulated compared to the mRNA levels after abnormal cervical 
dilatation, or in the uterus of women who are at term. (Paper 5) Although ERβ is highly 
expressed in the myometrium of women in term pregnancy, no correlation of the 
expression levels to cervical dilatation could be found. CYP7B1 did not differ between 
the three groups of women. The study also confirmed that the levels of 5AR1 were not 
correlated to progression of labour. 
In the present study a local differentiated metabolism of estradiol could not be 
detected, since the cytochrome P450 19A1 (aromatase), which is the main enzyme that 
metabolizes androgens to estradiol, did not vary between the groups. The up-regulation 
of ERα seems to be the main way of regulation of estradiol effects on myometrium.  
Earlier studies are inconsistent in their reporting of how ERα levels are affected 
during labour. This inconsistency may be explained by the fact that the progression of 
labour was not taken in to account 54, 73, 74. 
A local metabolism leading to “progesterone withdrawal” in the uterus may be a 
possible mechanism leading to the onset of labour. The levels of AKR1C3 mRNA, the 
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main enzyme along with 5AR1 that metabolizes progesterone, were not altered in this 
study design, where the levels in the lower segment of the myometrium were measured. 
Human labour is a complicated orchestration including the interplay between 
prostaglandins, oxytocin, progestins and estrogens. In this study, we could not find any 
correlation of androgen metabolising enzymes with progression of labour. Finally, the 
question remains, what mechanism/factor is actually conducting? 
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4 CONCLUSIONS 
 
• Homozygous carriers of the UGT2B17 gene have significantly higher 
expression of the enzyme at the mRNA level in the prostate  
• Lack of one allele of the UGT2B17 gene was associated with doubled 
risk of prostate cancer 
• A novel polymorphism has been identified in the promoter region of the 
CYP7B1 gene, the gene was otherwise well-conserved. 
• The allele frequency of this SNP on the CYP7B1 gene was too low, to 
substantially affect the prostate cancer risk among Swedes. 
• The CYP1B1 Val432Leu polymorphism was associated with miscarriage 
in the first trimester although it is not a risk factor for repeated 
miscarriage. 
• Repeated miscarriage is associated with future thyroid disease. 
• Smoking, but not obesity is associated with repeated miscarriage 
• Estrogen receptor alpha gene expression is associated with cervical 
ripening in the first stage of labour. 
• No association with dysfunctional labour was found for the expression of 
ER beta, 5AR1, AKR1C1-4, CYP7B1, or aromatase. 
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